Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2019-03-06 AGM Information
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for Holding a General Meeting on a Concentrated Date'. It explains why the company, InnoTherapy, is holding its annual general meeting on a date that coincides with the 'concentrated' dates identified by the KOSDAQ Association. Since this is a specific regulatory disclosure regarding meeting logistics and compliance with voluntary dispersion programs, and does not fit into the specific categories of AGM materials or proxy statements, it is classified as a general regulatory filing.
2019-03-06 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required when an entity or individual acquires or disposes of a significant percentage of a company's shares, crossing specific regulatory thresholds. Based on the provided definitions, this falls under the 'Major Shareholding Notification' category.
2019-02-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) disclosing a significant change in revenue or profit structure (30% or more). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial changes before the final audited annual report is published. Since it provides specific financial data (revenue, operating profit, net income) and is not a full annual report or a mere announcement of a report's availability, it falls under the category of an Earnings Release (ER) as it provides the initial highlights of financial performance. FY 2018
2019-02-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of major shareholders (Lee Moon-Sue and others) in the company 'InnoTherapy' following a new listing. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2019-02-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often filed via DART) to report insider shareholdings and changes in ownership by directors or major shareholders. This aligns with the 'Director's Dealing' category, which covers reports of personal share transactions by company directors and executives.
2019-02-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an individual (Lee Hae-Shin) regarding their holdings in InnoTherapy. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their share ownership and changes therein, which falls under the 'Director's Dealing' category.
2019-02-07 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.